01. Letter from the President

Dear Friends,

I hope this finds you well and that you all have had a chance to enjoy some relaxing summer vacation.

For those of you who participated in the June ECFS Conference in Seville, I am sure you will agree that it was a great success, and I would again like to thank the conference President Esther Quintana Gallego for her contribution to the event. I would also like to thank the local Cystic Fibrosis community and all the volunteers for their considerable and enthusiastic support. My sincere thanks go to the Scientific Committee who produced an excellent programme, and to the speakers, moderators and presenters for their superb contribution.

The ECFS continued its tradition of awarding grants to young researchers based on the merit of their submitted abstracts, and we were happy to support 20 young researchers with a Travel Grant. We also granted 3 Young Investigator Awards and were delighted to welcome the Young Investigator Awardees to the Closing Ceremony. All the award winners also received a 1 year free membership subscription to the ECFS.

Young Investigator Awards 2017:
On the picture, Katharina Staufer (AT) on the right, Katie Farrant (UK) in the middle. Yanan Wang (AU) could not be present for the picture.
To honour the enormous contribution of Prof. Gerd Döring, the ECFS has initiated a Gerd Döring Award in 2015 that is given annually to honour an exceptional early career young European scientist. This award includes a monetary grant of € 5000 to support research. This year, the Award was presented to Viola Camilla Scoffone (IT) for her manuscript entitled “Efflux-mediated resistance to a benzothiazol derivative effective against *Burkholderia cenocepacia*”, published in 2015 in *Frontiers in Microbiology*.

More information on the ECFS Awards

Once again, speakers at this year’s conference were asked to make their presentations (slides) available on the ECFS website (for members only) and these can be viewed by signing in under the “MY ECFS” tab on the homepage of our website [www.ecfs.eu](http://www.ecfs.eu).

This year in Seville, we also webcasted several sessions, amongst which the CF courses in English and Spanish, and we are working on making these available on the ECFS Education platform that will be launched shortly. We will keep you informed about the developments of our ECFS Education project.

Thanks go to all of you who participated to the Board elections. I would like to warmly congratulate Isabelle Fajac for her new position as President Elect. She will take over as ECFS President officially from the next Annual General Meeting at the Belgrade conference and I look forward to working closely with her over the coming months as I hand over the reins.

I take this opportunity to also congratulate Kevin Southern and Marcus Mall who are starting their second terms on the ECFS Board.

We are always pleased to see new initiatives and projects and I am happy to report that the ECFS Board recently approved two working groups: an international Working Group on antimicrobial resistance together with the American CF Foundation, the Canadian CF Foundation and the Australian CF Association; and an ECFS Working Group on fungal pathogens led by Carsten Schwarz.

We are well into the planning for the Basic Science Conference which will be held in Loutraki, on the Gulf of Corinth in Greece (21-24 March 2018), and the annual conference which will be held 06-09 June 2018 in Belgrade, Serbia. Programmes for both conferences will be available soon and we hope that you will take an active part in these events and consider submitting your best work for presentation and discussion. The abstract submission deadline for the conference in Belgrade will be 19 January 2018. More information about the conferences can be found on our website.

I would like to thank those members who participated in this year’s Annual General Meeting in Seville, and you will find the minutes from the meeting included in this Newsletter.

As always, I would like to remind you to please feel free to send us articles that you would like to have included in forthcoming newsletters as this provides a great vehicle for communication.

Best wishes,

Kris De Boeck, ECFS President
02. Annual General Meeting Minutes

For the latest dates of ECFS activities and meetings please refer to Point 09: Upcoming events

Minutes of the Annual General Meeting of the European Cystic Fibrosis Society

40th European Cystic Fibrosis Conference, Seville, Spain, 9th June 2017

Presiding Officer: Prof. Kris De Boeck

The meeting was opened at 18.30.
Number of Participants: 64

President’s Report

Prof. Kris De Boeck welcomed the ECFS members present and thanked them for their participation in the meeting. She hopes for higher number of participants at the AGM and invited all attendees to share a drink as a token of appreciation for their commitment to the ECFS.

She presented a slide listing the current ECFS Projects and Working Groups, and noted that reports on these activities had been provided ahead of the meeting and Coordinators of these projects would be ready to answer questions on their activities later on in the meeting.

Regarding ECFS conferences, she reported current figures of 2345 delegates registered for the Seville conference and a record number of 648 abstracts had been submitted. She announced more communication with the membership during the conference with the introduction of slideshows with important messages to the membership. She took the opportunity to thank the Conference President and all the other organizers for their contribution to a smooth preparation of the conference.

She went on to provide an overview of the ECFS activities this year, beginning with the Steering Committee meetings of the CTN and ECFS PR in January and the ECFS Diagnostic Network Working Group meeting in Ljubljana in February. She mentioned the highly successful Basic Science conference held in Albufeira, Portugal where a record number of abstract submissions were recorded.

The President then presented the programme of activities for 2017-2018 to include:

- ECFS Autumn Meeting, Indianapolis 1 November 2017
- CTN Steering Group Meeting, TBC 25-26 January 2018
- ECFS Winter Board Meeting, TBC 24 January 2018
- Registry Steering Group Meeting, TBC 26 January 2018
- ECFS Diagnostic Network WG Meeting, TBC February 2018
- 14th ECFS Basic Science Conference, TBC March 2018
- Young Investigators Meeting, Paris 21-23 February 2018
- 41st European CF Conference, Belgrade 6-9 June 2018

Prof. De Boeck presented the breadth of activities and plans ahead for the society.

- Continuing CFTR gene sequencing service with a goal to see 95% of patients with CF in every country to have 2 mutations identified by 2018
- ECFS mental health Working Group: the working group’s focus is on the dissemination and implementation of mental health guidelines in Europe as well as the monitoring and evaluation of mental health screening. The working group’s web pages on the ECFS website includes resources and links to translations of screening tools
- A strategic plan to maximize progress in CF therapies is being designed under the leadership of Jane Davies, London, UK. Documents related to Optimizing trial design, drug development for patients with rare CFTR mutations and speeding up access to successfully trialled drugs will be open for discussion
• **Education:** The ECFS Education project continues to expand and Prof De Boeck encouraged all to be generous with their slides and educational material and share with the wider CF community. An ECFS Education committee has been formed. The committee is chaired by Daniel Peckham and includes 1 representative of each ECFS Working group, Special Interest Group and project (standards of care, CTN, Registry). The aims of the committee are to work closely with members and support the development of a clear curriculum appropriate to each sub speciality. The committee will advise on existing educational resources to be referenced, assess unmet educational needs and support the development of educational modules.

• **ECFS Book:** the next ECFS book will be dedicated to infants and young children. The editors, Kevin Southern and Kris De Boeck have invited authors for the different chapters with a deadline of September for delivery of the chapters.

Prof. De Boeck presented some initiatives to further encourage participation of ECFS members to the activities of the Society.

- Board attendance at AGM
- ECFS Community bulletin boards (including job offers, collaborations asked and other announcements)
- Proposal box for ECFS members at the conference where suggestions for project opportunities and questions to ECFS board can be asked.
- Suggestions for tomorrow lounge activities
- Special interest groups associated with ECFS
- Social media
- Board elections on site: this year, elections were open until the day prior to the AGM. 152 members voted (electorate list included 819 members) and Prof De Boeck was disappointed only 10 members took advantage of the voting facility at the conference.

The audience was asked for any questions:

Silke van Koningsbruggen suggested having the election booth available at a central place, maybe in the conference registration area.

Daniel Peckham proposed to look into including the online voting on the ECFS app that will be developed.

Jaroslaw Walkowiak noted that attendance to the AGM shows commitment to the ECFS and suggested the votes to take place at the AGM only.

**Secretary’s Report**

Prof. Harm Tiddens reported the preliminary membership numbers for 2017 (until May) were 986, an increase in comparison with the figures reported at the same time frame in 2016. One of the reasons for this was the introduction of conference registration and membership subscription available to all attendees.

In view of the healthy financial situation of the Society, he was happy to inform the membership that there would be no increase to the standard subscription fee in 2018; it will remain at Euro 120. There will be a continued lower rate for some categories of members who do not wish to receive the Journal of Cystic Fibrosis (JCF):

- Allied Health Professionals, PhD Students and Post Docs - 50 € (*)
- Retired members still actively engaged in an ECFS Project or Working Group - Free (*)
- Corporate membership rate for colleagues from the industry - 220 € (full membership benefits but no voting rights).

(*) no JCF subscription associated with this rate

The discounted 3 years subscription (300 € instead of 360 €) introduced in 2015 will be offered as a membership possibility for the years 2018-2019-2020.

He communicated the results of the recent elections and was happy to announce the election of Prof. Isabelle Fajac as President Elect. The Board members elected are: Marcus Mall and Kevin Southern, who have been elected for a second term.

The audience was asked for any questions:
Vincent Gulmans asked about the possibility of granting voting rights to ECFS members affiliated with patient organizations.

→ This was recently discussed at an ECFS Board meeting and the request was not approved but the topic can be further discussed.

_Treasurer’s Report_

Prof. Harm Tiddens presented the audited ECFS Financial statement for the year 2016. The result of the year was very favourable, with a surplus of € 330,131 resulting in a positive balance for the Society’s net assets of € 2,906,334 at 31st December 2016. Prof. Tiddens informed the AGM that the full audited accounts will be posted on the website.

_Update on Journal of Cystic Fibrosis_

Prof. Scott Bell reported on developments of JCF. There were 409 submissions and 119 Original Research Articles and Reviews published in 2016. There has been a steady increase in the number of Science Direct downloads (over 500,000).

New initiatives and recent changes include:

- Editorial board: retiring members are Margarida Amaral, Garry Cutting, Sue Wolfe. Suzannah King is newly appointed as editor
- Lancet respiratory Medicine / JCF partnership: papers found more suitable to JCF than LRM sent to JCF
- Joint LRM/JCF symposium at conference: successful in Basel 2016 and Seville 2017
- Supplements: CFF Nutrition guidelines being submitted - ECFS Basic Science conference 2017 (mini reviews of symposia topics)
- CF Research News: high level of commitment (only 9/213 did not provide lay summary) ; 2016 - n=84

Finally, Prof Bell showed a slide with the Top Cites from the start of JCF. He encouraged guidelines to be published in JCF.

_Report from ECFS CTN_

Dr. Tim Lee presented a graph demonstrating the progression of studies conducted by the CTN since 2009. He also presented the evolution of the CTN services including number of protocols reviewed and number of feasibility checks performed. He reported 6 Protocol Reviews ongoing as of June 2017 and 3 Feasibilities finalized May 2017 as well as 7 ongoing or in setup.

He presented the ECFS CTN sites activity in 2016 with a median of 6 studies per site and a median 7% enrolment. He reported on the implementation of the Additional Research Capacity Award during 2017 to sites that had identified this as a significant barrier and met selection criteria.

All CTN sites have received detailed weighted quality reports and metrics and low performing sites will be offered the possibility to enter a coaching programme before reapplying to be part of the CTN. He announced a new ECFS CTN expansion for 2019 with applications open in the fall 2018.

Finally, he thanked the CTN team and all those committed in the different CTN committees for their hard work and dedication to the success of the CTN.

_Report from ECFS Standards of Care_

Dr. Pavel Drevinek reported on the progress of the Standards of Care project.

The best practice subgroup is reviewing and updating the 2014 Standards of Care. The document is to be reviewed by the ECFS Board before publication as open access.

The Quality Management subgroup is finalising a quality management module for the Education platform. A module for benchmarking across countries/centres is being developed in the ECFSTracker.

A successful Standards of Care symposium was held at the Seville conference with simultaneous translation in Spanish available.

The Standards of Care next steps will be looking at accreditation of CF centres or auditing of CF centres. Finally, Dr. Drevinek thanked Prof Martin Stern for his help and commitment to the Registry and Standards of Care Quality management group over the years.
**Report from ECFS Patient Registry**

Dr. Luz Naehrlich reported on the activities of the ECFS Patient Registry (ECFSPR). The ECFSPR is expanding its coverage with 31 countries participating and over 42,000 CF patients. He reported on the different ECFSPR groups:

- the Data Quality Group with aim to ensure accuracy and quality of data
- the Definitions Group focuses on reviewing variables and definitions
- the Global CF harmonisation project aims to harmonise variables & definitions to allow comparison worldwide
- the Pharmacovigilance project is currently developing a procedure with EMA
- the Patient awareness project develops at a glance report, Posters in cooperation with CF Europe to bring data closer to patients

Finally, Dr Naehrlich thanked Dr. McKone for his leadership of the ECFSPR over the last 3 years.

**Reports from ECFS Working Groups**

Prior to the Annual General Meeting, members had been sent the progress reports from the ECFS Working Groups.

Current Working Groups:
- Diagnostics Network Working Group
- Exercise Working Group
- Neonatal Screening Working Group
- Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group
- Mental Health Working Group

The audience was asked for any questions: None received.

**Special Interest Groups**

Prof De Boeck reported on Special Interest Groups and their affiliation with ECFS:
- ECFS affiliated:
  - ECFS Nursing Special interest Group (ECFS NSiG)
  - European Cystic Fibrosis Pharmacy Group (ECFPG)
- ECFS Psychosocial Working Group
- European Cystic Fibrosis Nutrition Group

not ECFS affiliated:
- International Physiotherapy Group for Cystic Fibrosis

**Annual Conference 2018**

A slide was shown presenting the 41st ECFS conference, to be held in Belgrade, Serbia, 6-9 June 2018.

Questions/Comments received: None

**Any Other Business**

None

With no further items being raised, the meeting ended at 19.30.
03. ECFS Board elections

We held Board elections in June. We are happy to announce that Prof. Isabelle Fajac has been elected as ECFS President Elect and will become President of the ECFS at the AGM in June 2018. Prof. Marcus Mall and Prof. Kevin Southern have been elected as Board Members for a second term.

04. JCF Impact factor

The official 2016 Impact Factors (IF) were released in July, and the Journal of Cystic Fibrosis (JCF) has increased its IF from a 2015 IF of 3.853 to 4.727. JCF ranks 8th of 59 in the Respiratory System category.

The Journal Impact Factor is published each year by Thomson Reuters. It is a measure of the number of times an average paper in a particular journal is cited during the preceding two years.

JCF has continued to work hard for this achievement, through thoughtful structuring of its editorial pages and continuing growth in our international presence. The ECFS would like to thank the Editor in Chief, Prof. Scott Bell, and the Editorial Board. Their excellent service and work have helped JCF gain its current standings and continue to aid its growth.

05. Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, How and Why? Live webinar

A free live webinar from the Elsevier Office of Continuing Medical Education will be organised on 02 October 2017, at 22:00 CET | 21:00 BST | 16:00 EDT - Tuesday 3 October 2017 at 7:00AM AEDT.

This live webinar is a roundtable discussion between three international expert faculty in cystic fibrosis (CF). This expert faculty will discuss the role of aerosolized agents for improving airway clearance, including caveats from their own extensive clinical experience in managing patients with this condition. The faculty will also deliberate on strategies to improve patient adherence to aerosolized CF therapies in a case study based format. The discussions at the webinar will support participants in clinical decision making as well as in helping their patients achieve optimal benefit through adherence to their aerosolized therapies for airway clearance in CF.

FACULTY
Chair: Professor John P. Clancy, MD
Faculty: Professor Kevin W. Southern, MBChB, MRCP, FRCPCCH, PhD
Professor Sarath Ranganathan, MBChB, MRCP, FRCPCCH, FRACP, PhD

More information
06. Job postings

As from 01 January 2018, a Post-doctoral Position will be available at the Department of Cell Physiology and Metabolism of the Geneva Medical Faculty.
Contact person: Dr. Marc Chanson
Deadline for applications: 15 October 2017
Detailed offer

07. Questionnaire: The treatment “in real life” of first detected PSA in children with CF in different European countries.

Under supervision of Prof Dr. M. Ballmann, Isabell Weber from Rostock University Medical Center is conducting a Europe-wide comparison on the eradication of first proven Pseudomonas aeruginosa (PSA) infection in children with cystic fibrosis.

With this questionnaire, her objective is to compare the treatment “in real life” of first detected PSA in children with CF in different European countries.
The questionnaire can be completed online with the link below. You will need a password: psa2017

https://evasys.uni-rostock.de/evasys/online.php?p=psa2017

Should you prefer to use a paper version, please print out the pdf- file via the link below and fax it when filled to +49 381 494 7028.

You can find more information hereunder:
Description of the study
Questionnaire

08. ECFS Award - Dr. Jeffrey Beekman

In Seville, we were happy to hand over the ECFS Award to Dr. Jeffrey Beekman. This award acknowledges Dr Beekman’s remarkable contribution to cystic fibrosis, initiating a breakthrough in the field by developing a functional CFTR assay in the CF intestinal organoid model developed in Utrecht. This has brought major advances to the field of this orphan disease, not only for developing and evaluating therapies in the context of personalized medicine, but also for diagnostic purposes and beyond.

2017 is definitely a great year for Dr Beekman as he also received the Excellence Award from the European Respiratory Society in Milan earlier this month.
Once again we extend our congratulations!
09. Upcoming Events

**Indiaoplis, IN, US**
01 November 2017:
ECFS Board Meeting
02-04 November 2017:
32nd North American Cystic Fibrosis Conference

**Brussels, Belgium**
24 January 2018:
ECFS Winter Board Meeting
25 January 2018:
ECFS Standards of Care Meeting
25-26 January 2018:
ECFS CTN Steering Group Meeting
ECFS Patient Registry Steering Group Meeting

**St Gallen, Switzerland:**
08-10 February 2018
ECFS Diagnostic Network Working Group Meeting

**Paris, France**
21-23 February 2018
12th European Young Investigators Meeting

**Belgrade, Serbia**
05 June 2018:
ECFS Board Meeting
06-09 June 2018:
41st European CF Conference

**Loutraki, Greece**
21-24 March 2018
ECFS 15th Basic Science Conference

10. Deadlines

- Abstract submission Young Investigator Meeting 01 November 2017
- Abstract submission 15th ECFS Basic Science conference 12 January 2018
- Abstract submission ECFS Conference Belgrade 19 January 2018
- Nomination ECFS Award 15 February 2018
- Nomination Gerd Döring Award 15 February 2018
- Nomination ECFS Elections 30 March 2018
The ECFS would like to thank all those who took the time to answer the ECFS 2017 Survey after the conference in Seville. The answers and comments help us to keep on improving our conferences. As announced, three free registrations to the next ECFS Conference in Belgrade were selected from the respondents.

We congratulate the winners:
- Sabina Wiecek, Katowice, Poland
- Kay Ramsay, Brisbane, Australia
- Darren Sills, Nottingham, United Kingdom

12. Current references in CF

Please scroll to next page for full list.
Antimicrobials


Akdag Cayli YA, Sahin S, Buttini F, Balducci AG, Montanari S, Vural I, Oner L. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients Drug Development and Industrial Pharmacy 2017; 43: 1378 - 1389

Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, Dick T. Rifabutin Is Active against Mycobacterium abscessus Complex Antimicrobial Agents and Chemotherapy 2017; 61: e00155-17


Bernardes EV, Charron-Mazenod L, Reading DJ, Reckseidler-Zenteno SL, Lewenza S. Expolysaccharide-Depressing Small Molecules with Antibiofilm and Antivirulence Activity against Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy 2017; 61: 56e01997-16


Caumo DTM, Geyer LB, Teixeira AR, Barreto SM. Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review Brazilian Journal of Otorhinolaryngology 2017; 83: 464 - 474


Greenwood J., Schwarz C., Sommerwerck U., Nash EF., Tamm M., Cao WH., Mastoridis P., Debonnett L., Hamed K.,
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
Therapeutic Advances in Respiratory Disease 2017; 11: 249 - 260
Gruber M., Moser I., Nagl M., Lackner M.,
Bactericidal and Fungicidal Activity of N-Chlorotaurine Is Enhanced in Cystic Fibrosis Sputum Medium
Antimicrobial Agents and Chemotherapy 2017; 61: 5:e02527-16
Handelsman JA., Nasr SZ., Pitts C., King WM.,
Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides
Pediatric Pulmonology 2017; 52: 1157 - 1162
Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis
Molecular Therapy 2017; 25: 2104 - 2116
LeCleir LK., Pettit RS.,
Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients
Pediatric Pulmonology 2017; 52: 1000 - 1005
Lendermon EA., Coon TA., Bednash JS., Weathington NA., McDyer JF., Mallampalli RK.,
Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation
Respiratory Research 2017; 18: ArNo: 131
Lexmond AJ., Hagedoor P., Frijlink HW., Rottier BL., de Boer AH.,
Prerequisites for a dry powder inhaler for children with cystic fibrosis
Mardirossian M., Pompelio A., Degasperi M., Runti G., Pacor S., Di Bonaventura G., Scocchi M.,
D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection
Frontiers in Chemistry 2017; 5: ArNo: 40
Maselli DJ., Keyt H., Restrepo MI.,
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases
International Journal of Molecular Sciences 2017; 18: 5:1062
Mashat M., Clark BJ., Assi KH., Chrystyn H.,
Assessment of recent nebulizer delivery systems using urinary pharmacokinetics method and aerodynamic characteristics of TOBI (R) nebulized dose following inhalation
Mazer DM., Young C., Kalikin LM., Spilker T.,
In Vitro Activity of Cefotolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli
Antimicrobial Agents and Chemotherapy 2017; 61: 9:e0076-17
Murakami K., Ono T., Viducic D., Somiya Y., Kariyama R., Horii K., Amoh T., Hirota K., Kumon H., Parske MR., Miyake Y.,
Role of p sl Genes in Antibiotic Tolerance of Adherent Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy 2017; 61: 7:e02587-16
Mustafa MH., Khandekar S., Tunney MM., Elborn JS., Kahl BC., Denis O., Piesiat P., Traore H., Tulenkens PW., Vanderbist F., Van Bambeke F.,
Acquired resistance to macrolides in Pseudomonas aeruginosa from cystic fibrosis patients
European Respiratory Journal 2017; 49: 5:1601847
Narayanaswamy VP., Giatpalboon S., Baker SM., Wiesmann WP., LiPuma JJ., Townsend SM.,
Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem
Nichols DP., Hoppoldt CL., Bratcher PE., Caceres SM., Chmiel JF., Malcolm KC., Saavedra MT., Salmon L., Taylor-Cousar JL., Nick JA.,
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 358 - 366
Olivares E., Badel-Berchoux S., Provot C., Jaulhac B., Prevost G., Bernardi T., Jhel F.,
Tobramycin and Amikacin Delays Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
Frontiers in Microbiology 2017; 8: ArNo: 1289
Olveira C., Padilla A., Dorado A., Contreras V., Garcia-Fuentes E., Rubio-Martin E., Porras N., Dona E., Carmona A., Oliveira G.,
Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin
Eurasian Journal of Medicine 2017; 49: 1162 - 123
Panguluri S., Gunda P., Debonnett L., Hamed K.,
Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
Clinical Drug Investigation 2017; 37: 795 - 805
Papp-Walace KM., Becka SA., Zeiser ET., Ohuchi N., Mojica MF., Gatta JA., Falleni M., Tosi D., Borghi E., Winkler ML., Wilson BM., LiPuma JJ., Hukama M., Bonom RA.,
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Cefazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients
ACS Infectious Diseases 2017; 3: 502 - 511
Ramanathan B., Jindal HM., Le CF., Gudimella R., Anwar A., Razali R., Poole-Johnson J., Manikam R., Sekaran SD.,
Next generation sequencing reveals the antibiotic resistant variants in the genome of Pseudomonas aeruginosa
Rello J., Sole-Lleonart C., Rouby JJ., Chastre J., Blot S., Poulakou G., Luyt CE., Riera J., Palmer LB., Pereira JM., Felton T., Dhanani J., Bassetti M., Welte T., Roberts JA.,
Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases
Clinical Microbiology and Infection 2017; 23: 629 - 639
Sans-Serramitjana U., Jorba M., Pedraz JL., Vinuesa T., Vinuesa M.,
Determination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC- colistin
Sierra JM., Fuste E., Rabanal F., Vinuesa T., Vinuesa M.,
An overview of antimicrobial peptides and the latest advances in their development
Expert Opinion on Biological Therapy 2017; 17: 663 - 676
Smyth AR., Bhatt J., Nevitt SJ.
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 3:CD002009

Smyth AR., Rosenfeld M.
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 4:CD001912

Tan JH., Vidalilac C., Yam JKH., Chua SL., Givskov M., Yang L.
In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm
Antimicrobial Agents and Chemotherapy 2017; 61: 7:e02223-16

Torge A., Wagner S., Chaves PS., Oliveira EG., Gutieres SS., Pohlmann AR., Titz A., Schneider M., Beck RCR.
Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis
International Journal of Pharmaceutics 2017; 527: 92 - 102

Trang TP., Hanretyt AM., Langelier C., Yang K.
Use of isavuconazol in a patient with voriconazole-induced QTc prolongation
Transplant Infectious Disease 2017; 19: 4:e12712

Tureli NG., Torge A., Juntek J., Schwarz BC., Schneider-Daun N., Tureli AE., Lehr CM., Schneider M.
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P-aeruginosa lung infections
European Journal of Pharmaceutics and Biopharmaceutics 2017; 117: 363 - 371

Veitkova N., Wells JM.
Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients
Current Drug Targets 2017; 18: 687 - 695

Waters V., Ratjen F.
Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 6:CD006961

Waters V., Yau Y., Beaudoin T., Wettlauer J., Tom SK., McDonald N., Rizvi L., Klingel M., Ratjen F., Tullis E.
Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection
Journal of Cystic Fibrosis 2017; 16: 492 - 495

Zobell JT., Epps KL., Young DC.
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update
Pediatric Pulmonology 2017; 52: 863 - 865

Cardiology

Sayyid ZN., Sellers ZM.
Technological advances shed light on left ventricular cardiac disturbances in cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 454 - 464

Cell Biology

Biswas R., Kumar P., Pollard HB.
Regulation of mRNA turnover in cystic fibrosis lung disease
Wiley Interdisciplinary Reviews-rna 2017; 8: 4:UNSP e1408

Guerra L., D’Oria S., Favia M., Castellani S., Santostasi T., Polizzii AM., Marigio MA., Gallo C., Casavola V., Montemurro P., Leonetti G., Manca A., Conese M.
CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy
Pediatric Pulmonology 2017; 52: 900 - 908

beta-Sitosterol Reduces the Expression of Chemotactic Cytokine Genes in Cystic Fibrosis Bronchial Epithelial Cells
Frontiers in Pharmacology 2017; 8: ArNo: 236

Macedo AN., Mathiapiaraman S., Brick L., Keenan K., Gonska T., Pedder L., Hill S., Britz-Mckibbin P.
The Sweat Metabolome of Screen-Positive Cystic Fibrosis Infants: Revealing Mechanisms beyond Impaired Chloride Transport
ACS Central Science 2017; 3: 904 - 913

Sailland J., Grosche A., Baumlin N., Dennis JS., Schmid A., Krick S., Salathe M.
Role of Smad3 and p38 Signalling in Cigarette Smoke-induced CFTR and BK dysfunction in Primary Human Bronchial Airway Epithelial Cells
Scientific Reports 2017; 7: ArNo: 10506

CFTR

Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-I-dependent trafficking of CFTR in the intestine
Physiological Reports 2017; 5: 11:e13299

Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell
Nature Communications 2017; 8: ArNo: 398

The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis

Bertrand CA., Mitra S., Mishra SK., Wang XH., Zhao Y., Pilewski JM., Madden DR., Frizzell RA.
The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9
American Journal of Physiology-lung Cellular and Molecular Physiology 2017; 312: L912 - L925

Bodas M., Silverberg D., Walworth K., Brucia K., Vij N.
Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function
Antioxidants & Redox Signaling 2017; 27: 433 - 451

Bossmann M., Ackermann BW., Thome UH., Laube M.
Signaling Cascade Involved in Rapid Stimulation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Dexamethasone
International Journal of Molecular Sciences 2017; 18: 8:1807
Wang GY.
Mechanistic insight into the heme-independent interplay between iron and carbon monoxide in CFTR and Slo1 BKCa channels
*Metallomics* 2017; 9: 634 - 645

Wang Y., Lin YH., Wu YN., Chen YL., Lin YC., Cheng CY., Chiang HS.
Loss of SLC9A3 decreases CFTR protein and causes obstructed azospernia in mice
*PLoS Genetics* 2017; 13: 4e1006715

Xue XJ., Mutymav V., Thakerar A., Mobley J., Bridges RJ., Rowe SM., Keeling KM., Bedwell DM.
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
*Human Molecular Genetics* 2017; 26: 3116 - 3129

Yan TY., Leng YM., Yang X., Gong YP., Sun HQ., Wang K., Xu WM., Zheng YH., Naren DL., Shi R.
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of PH plus leukemia through the HDAC2-mediated PTEN pathway
*Leukemia Research* 2017; 57: 9 - 19

Yang AN., Sun Y., Mao CY., Yang SH., Huang M., Deng M., Ding N., Yang XL., Zhang MH., Jin SJ., Xiang YD., Huang Y.
Folate Protects Hepatocytes of Hyperhomocysteinemia Mice From Apoptosis via Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) - Activated Endoplasmic Reticulum Stress
*Journal of Cellular Biochemistry* 2017; 118: 2921 - 2932

Zhang JT., Wang Y., Chen JJ., Zhang XH., Da Dong J., Tsang LL., Huang XR., Cai ZM., Lan HY., Jiang XH., Chan H.C.
Defective CFTR leads to aberrant beta-catenin activation and kidney fibrosis
*Scientific Reports* 2017; 7: ArNo: 5233

Clinical

Aziz DA., Billoo AG., Qureshi A., Khalid M., Kirmani S.
Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan
*Pakistan Journal of Medical Sciences* 2017; 33: 554 - 559

Coriati A., Arslanian E., Bouvet GF., Prat A., Seidah NG., Rabasa-Lhoret R., Berthiaume Y.
Proprotein Convertase Subtilisin/Kexin type 9 affects insulin but not lipid metabolism in cystic fibrosis
*Clinical and Investigative Medicine* 2017; 40: E59 - E65

Leite CF., Folescu TW., Firmida MD., Cohen RWF., Leao RS., de Freitas FAD., Albano RM., da Costa CH., Marques EA.
Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre
*BMC Pulmonary Medicine* 2017; 17: ArNo: 100

Mandavdhare HS., Kumar A., Sharma V., Rana SS.
Pancreatic lipomatosis in cystic fibrosis: Rare manifestation of an uncommon disease
*Intractable & Rare Diseases Research* 2017; 6: 150 - 151

Marson FAL., Bertuzzo CS., Ribeiro JD.
Personalized or Precision Medicine? The Example of Cystic Fibrosis
*Frontiers in Pharmacology* 2017; 8: ArNo: 390

McColley SA., Schechter MS., Morgan WJ., Pasta DJ., Craib ML., Konstan MW.
Risk factors for mortality before age 18 years in cystic fibrosis
*Pediatric Pulmonology* 2017; 52: 909 - 915

Ramos KJ., Quon BS., Heitshe SL., Mayer-Hamblett N., Lease ED., Aitken ML., Weiss NS., Goss CH.
Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States
*Chest* 2017; 151: 1320 - 1328

Ranganathan SC., Hall GL., Sly PD., Stick SM., Douglas TA.
Early Lung Disease in Infants and Preschool Children With Cystic Fibrosis What Have We Learned and What Should We Do about it?
*American Journal of Respiratory and Critical Care Medicine* 2017; 195: 1567 - 1575

Reznikov LR.
Cystic Fibrosis and the Nervous System
*Chest* 2017; 151: 1147 - 1155

Ronan NJ., Elborn JS., Plant BJ.
Current and emerging comorbidities in cystic fibrosis
*Pulmonary Medicine* 2017; 17: ArNo: 100

Somayaji R., Ramos KJ., Kapnadak SG., Aitken ML., Goss CH.
Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency)
*Pulmonary Medicine* 2017; 17: E125 - E138

Wang YY., Lin YH., Wu YN., Chen YL., Lin YC., Cheng CY., Chiang HS.
Loss of SLC9A3 decreases CFTR protein and causes obstructed azospernia in mice
*PLoS Genetics* 2017; 13: 4e1006715

Xue XJ., Mutymav V., Thakerar A., Mobley J., Bridges RJ., Rowe SM., Keeling KM., Bedwell DM.
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
*Human Molecular Genetics* 2017; 26: 3116 - 3129

Yan TY., Leng YM., Yang X., Gong YP., Sun HQ., Wang K., Xu WM., Zheng YH., Naren DL., Shi R.
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of PH plus leukemia through the HDAC2-mediated PTEN pathway
*Leukemia Research* 2017; 57: 9 - 19

Yang AN., Sun Y., Mao CY., Yang SH., Huang M., Deng M., Ding N., Yang XL., Zhang MH., Jin SJ., Xiang YD., Huang Y.
Folate Protects Hepatocytes of Hyperhomocysteinemia Mice From Apoptosis via Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) - Activated Endoplasmic Reticulum Stress
*Journal of Cellular Biochemistry* 2017; 118: 2921 - 2932

Zhang JT., Wang Y., Chen JJ., Zhang XH., Da Dong J., Tsang LL., Huang XR., Cai ZM., Lan HY., Jiang XH., Chan H.C.
Defective CFTR leads to aberrant beta-catenin activation and kidney fibrosis
*Scientific Reports* 2017; 7: ArNo: 5233

Zhang Z., Liu FY., Chen J.
Conformational Changes of CFTR upon Phosphorylation and ATP Binding
*Cell* 2017; 170: 483 - 495

Diabetes

Boudreau V., Dubois CL., Desjardins K., Mailhot M., Tremblay F., Rabasa-Lhoret R.
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?
*International Medical Case Reports Journal* 2017; 10: 243 - 246

Wood J., Mulrennan S., Hill K., Cecins N., Morey S., Jenkins S.
Telehealth clinics increase access to care for adults with cystic fibrosis living in rural and remote Western Australia
*Journal of Telemedicine and Telecare* 2017; 23: 673 - 679

Diabetes

Boudreau V., Dubois CL., Desjardins K., Mailhot M., Tremblay F., Rabasa-Lhoret R.
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 885 - 895

Hoyert L., Jabarpour-Bonyadi M., Ghofraneh M., Pradhan R., Rafeey M.
Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population
*Tuberculosis and Respiratory Diseases* 2016; 79: 267 - 273

Walayat S., Hussain N., Patel J., Hussain F., Patel P., Dhillon S., Aulakh B., Chittivelu S.
Drug-induced dyspnea versus cystic fibrosis exacerbation: a diagnostic dilemma
*International Medical Case Reports Journal* 2017; 10: 243 - 246

Boudreau V., Dubois CL., Desjardins K., Mailhot M., Tremblay F., Rabasa-Lhoret R.
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?
*International Medical Case Reports Journal* 2017; 10: 243 - 246

Wood J., Mulrennan S., Hill K., Cecins N., Morey S., Jenkins S.
Telehealth clinics increase access to care for adults with cystic fibrosis living in rural and remote Western Australia
*Journal of Telemedicine and Telecare* 2017; 23: 673 - 679

Diabetes

Boudreau V., Dubois CL., Desjardins K., Mailhot M., Tremblay F., Rabasa-Lhoret R.
Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 885 - 895

Cystic fibrosis-related diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function
*Journal of Pediatric Endocrinology & Metabolism* 2017; 30: 815 - 821
Zoni AC., Dominguez-Berjon MF., Estebar-Valsallo MD., Sendra JM., Astrap-Mochales J. Epidemiology of cystic fibrosis-related diabetes in Madrid (Spain) and frequency of hospitalization European Journal of Internal Medicine 2017; 42: E14 - E15

Diagnosis

Choi DH., Li Y., Cutting GR., Searson PC. A wearable potentiometric sensor with integrated salt bridge for sweat chloride measurement Sensors and Actuators B-chemical 2017; 250: 673 - 678
Durc P., Foret F., Pokojova E., Homola L., Skrickova J., Herout V., Dastych M., Vinohradska H., Kuban P. New approach for cystic fibrosis diagnosis based on chloride/potassium ratio analyzed in non-invasively obtained skin-wipe sweat samples by capillary electrophoresis with contactless conductometric detection Analytical and Bioanalytical Chemistry 2017; 409: 3507 - 3514
Faria AG., Marson FAL., Ribeiro AF., Ribeiro JD. The correlation between age and sweat chloride levels in sweat tests Revista Portuguesa de Pneumologia 2017; 23: 227 - 230
Naehrig S., Chao CM., Naehrlich L. Cystic Fibrosis Diagnosis and Treatment Deutsches Arzteblatt International 2017; 114: 564 - 567
Pedersen KBF. Diagnosing cystic fibrosis by elevated sodium concentration in saliva Trace Elements and Electrolytes 2017; 34: 107 - 110

Epidemiology

Isaacs D. Survival comparison of patients with cystic fibrosis in Canada and the USA Journal of Paediatrics and Child Health 2017; 53: 922

Kelly J. Environmental scan of cystic fibrosis research worldwide Journal of Cystic Fibrosis 2017; 16: 367 - 370
Stephenson AL., Stanojevic S., Sykes J., Burgel PR. The changing epidemiology and demography of cystic fibrosis Presse Medicaile 2017; 46: E87 - E95

Exerise

Sani M., Ayubi E. Relationship between lung function and Modified Shuttle Test performance in adult patients with cystic fibrosis: a methodological issue Physiotherapy 2017; 103: 336 - 337

Gastroenterology

Garcia JC., Gutierrez IC., Monte BG., Jimenez IR. Prenatal diagnosis of fetal bowel obstruction with complicated mi associated with cystic fibrosis Avances en Biomedicina 2017; 6: 63 - 68

Gene Therapy

Guggino WB., Cebotaru L. Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments Expert Opinion on Biological Therapy 2017; 17: 1265 - 1273
Naso MF., Tomkowicz B., Perry WL., Strohl WR. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy BioDrugs 2017; 31: 317 - 334
General Review

Burgel PR., Fajac I.
Cystic fibrosis: Current aspects and perspectives
Presse Medecine 2017; 46: E85 - E86

Klimova B., Kuca K., Novotny M., Maresova P.
Cystic Fibrosis Revisited - a Review Study
Medicinal Chemistry 2017; 13: 102 - 109

Savant AP., McCollely SA.
Cystic fibrosis year in review 2016
Pediatric Pulmonology 2017; 52: 1092 - 1102

Zemanick ET., Daines CL., Dellon EP., Esther CR., Kinghorn B., Ong T., Muhlebach MS.
Highlights from the 2016 North American Cystic Fibrosis Conference
Pediatric Pulmonology 2017; 52: 1103 - 1110

Genetics

De Wachter E., Thomas M., Wanyama SS., Seneca S., Malfroot A.
What can the CF registry tell us about rare CFTR mutations? A Belgian study
Orphanet Journal of Rare Diseases 2017; 12: ArNo: 142

El-Seedy AS., Shafiek H., Kitizs A., Ladeveze V.
CFTR Gene Mutations in the Egyptian Population: Current and Future Insights for Genetic Screening Strategy
Frontiers in Genetics 2017; 8: ArNo: 37

The importance of functional tests to assess the effect of a new CFTR variant when genotype-phenotype correlation is not possible
Clinical Case Reports 2017; 5: 658 - 663

Hull BP., Jiramongkolchai P., Turner JH., Olson L., Chandra RK.
Single nucleotide polymorphisms related to cystic fibrosis in chronic rhinosinusitis-a pilot study
International Forum of Allergy & Rhinology 2017; 7: 467 - 473

Jiang LY., Jin JM., Wang SS., Zhang FX., Dai YD., Shi LB., Zhang SY.
CFTR gene mutations and polymorphism are associated with non-obstructive azoospermia: From case-control study
Gene 2017; 626: 282 - 289

Liu KQ., Liu YP., Li X., Xu KF., Tian XL., Zhang X.
A novel homozygous complex deletion in CFTR caused cystic fibrosis in a Chinese patient
Molecular Genetics and Genomics 2017; 292: 1083 - 1089

MacKenzie IER., Paquette V., Gosses F., George S., Chappe F., Chappe V.
Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L
Journal of Cystic Fibrosis 2017; 16: 335 - 341

Ozkan-Ariksoyosal D.
Electrochemical Determination of Cystic Fibrosis Gene Mutation by Magnetic Beads-Based Disposable Kit-type Biosensor
Journal of the Electrochemical Society 2017; 164: B258 - B266

Clinical Genetics 2017; 92: 115 - 116

Sawicki GS., McKone EF., Millar SJ., Pasta DJ., Konstan MW., Lubarsky B., Wagener JS.
Patients with Cystic Fibrosis and a G551D or Homozygous P508del Mutation: Similar Lung Function Decline
American Journal of Respiratory and Critical Care Medicine 2017; 195: 1673 - 1676

Regulatory dynamics of 11p13 suggest a role for EHF in modifying CF lung disease severity
Nucleic Acids Research 2017; 45: 8773 - 8784

Szczesniak RD., Li D., Su WJ., Brokamp C., Pestian J., Seid M., Clancy JP.
Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood

Growth & Development

A retrospective analysis of longitudinal changes in bone mineral content in cystic fibrosis
Journal of Pediatric Endocrinology & Metabolism 2017; 30: 807 - 814

Doulgeraki A., Petrochelioi A., Petrochelioi G., Chrousos G., Doubdounakis SE., Kaditis A.
Body composition and lung function in children with cystic fibrosis and meconium ileus
European Journal of Pediatrics 2017; 176: 737 - 743

Excess weight in patients with cystic fibrosis: is it always beneficial?
Nutrition Hospitarlaria 2017; 34: 578 - 583

Gupta S., Mukeierjee A., Khagawat R., Kabra M., Lodha R., Kabra SK.
Bone Mineral Density of Indian Children and Adolescents with Cystic Fibrosis
Indian Pediatrics 2017; 54: 545 - 549

Modoussou A.J., Golzar A., Hassanazad M., Sayedi S.J., Velayati A.
Low Bone Mineral Density and Associated Factors in Patients with Cystic Fibrosis: A Cross-Sectional Study

Obmann VC., Christie A., Ebner L., Szucs-Farkas Z., Ott SR., Yarram S., Stanzinger E.
Bone subtraction radiography in adult patients with cystic fibrosis
Acta Radiologica 2017; 58: 929 - 936

Sharma S., Jaksic M., Fenwick S., Byrnes C., Cundy T.
Accrual of Bone Mass in Children and Adolescents with Cystic Fibrosis
Journal of Clinical Endocrinology & Metabolism 2017; 102: 1734 - 1739

Usatin D., Yen EH., McDonald C., Asfour F., Pohl J., Robson J.
Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes
Journal of Cystic Fibrosis 2017; 16: 503 - 509
Immunology & Inflammation

Bielen K., Jongers BS., Boddart J., Raju TK., Lammens C., Malhotra-Kumar S., Jorens PG., Goossens H., Kumar-Singh S.
Biofilm-Induced Type 2 Innate Immunity in a Cystic Fibrosis Model of Pseudomonas aeruginosa
Frontiers in Cellular and Infection Microbiology 2017; 7: ArNo: 274

Boikos C., Papenburg J., Martineau C., Joseph L., Scheifele D., Chivers M., Lands LC., De Serres G., Quacch C.
Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis Human Vaccines & Immunotherapeutics 2017; 13: 1254 - 1260

Clauzure M., Valdivieso AG., Massip-Copiz MM., Mori C., Dugour AV., Figueroa JM., Santa-Coloma TA.
Intracellular Chloride Concentration Changes Modulate IL-1 Expression and Secretion in Human Bronchial Epithelial Cultured Cells
Journal of Cellular Biochemistry 2017; 118: 2131 - 2140

Transcriptomic profile of cystic fibrosis patients identifies type I interferon response and ribosomal stalk proteins as potential modifiers of disease severity

Kovacic B., Sehl C., Wilker B., Kamler M., Gulbins E., Becker KA.
Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs
Cellular Physiology and Biochemistry 2017; 41: 1208 - 1218

Leveque M., Le Trionnaire S., Del Porto P., Martin-Chouly C.
The impact of impaired macrophage functions in cystic fibrosis disease progression
Journal of Cystic Fibrosis 2017; 16: 443 - 453

Marteyn BS., Burgel PR., Meijer AH., O'Callaghan D., Meijer L., Witko-Sarsat V.
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by Pseudomonas aeruginosa: Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis
Frontiers in Cellular and Infection Microbiology 2017; 7: ArNo: 243

Mauch RM., Rossi CL., Aiello TB., Ribeiro JD., Ribeiro AF., Holby N., Levy CE.
Secretory IgA response against Pseudomonas aeruginosa in the upper airways and the link with chronic lung infection in cystic fibrosis
Pathogens and Disease 2017; 75: 6:ftx069

Mesureur J., Feliciano JR., Wagner N., Gomes MC., Zhang LL., Blanco-Gonzalez M., van der Vaart M., O'Callaghan D., Meijer AH., Vergunst AC.
Macrophages, but not neutrophils, are critical for proliferation of Burkholderia cenocepacia and ensuing damaging inflammation
Plos Pathogens 2017; 13: 6:e1006437

Monaghan TM., Negm OH., MacKenzie B., Hamed MR., Shone CC., Humphreys DP., Acharya KR., Wilcox MH.
High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection
Clinical and Experimental Gastroenterology 2017; 10: 169 - 175

Noel S., Panin N., Beka M., Dhooghe B., Huaux F., Leal T.
Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms
Clinical Science 2017; 131: 1107 - 1121

Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study
Lung 2017; 195: 445 - 453

Tarique AA., Sly PD., Holt PG., Bosco A., Ware RS., Logan J., Bell SC., Wainwright CC., Fantino E.
CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 475 - 482

Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
eBiomedicine 2017; 23: 173 - 184

Liver Disease

Klotter V., Gunchick C., Siemers E., Rath T., Hudel H., Naehrlich L., Roderfeld M., Roeb E.
Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study

Adult-Onset Cystic Fibrosis Liver Disease: Diagnosis and Characterization of an Underappreciated Entity
Hepatology 2017; 66: 591 - 601

Vitamin K status in cystic fibrosis patients with liver cirrhosis
Digestive and Liver Disease 2017; 49: 672 - 675

Palaniappan SK., Than NN., Thein AW., Moe S., van Mourik I.
Interventions for preventing and managing advanced liver disease in cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 8:CD012056

Meeting Abstracts

Abstracts of the 40th European Cystic Fibrosis Conference Seville, Spain, 7-10 June 2017 Abstracts
Journal of Cystic Fibrosis 2017; 16:

Microbiology

Agnoli K., Freitag R., Gomes MC., Jenul C., Suppiger A., Mannweiler O., Frauenknecht C., Janser D., Vergunst AC., Ebert L.
Use of Synthetic Hybrid Strains To Determine the Role of Replicon 3 in Virulence of the Burkholderia cepacia Complex
Applied and Environmental Microbiology 2017; 83: 13:UNSP e00461

Andersen SB., Ghoul M., Griffin AS., Petersen B., Johansen SK., Molin S.
Diversity, Prevalence, and Longitudinal Occurrence of Type II Toxin-Antitoxin Systems of Pseudomonas aeruginosa Infecting Cystic Fibrosis Lungs
Frontiers in Microbiology 2017; 8: ArNo: 1180
Gade SS., Norskov-Lauritsen N., Ridderberg W. Prevalence and species distribution of Achromobacter sp cultured from cystic fibrosis patients attending the Aarhus centre in Denmark. *Journal of Medical Microbiology* 2017; 66: 686 - 689


Hewer SCL., Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. *Cochrane Database of Systematic Reviews* 2017; : 4:CD004197


Jones CJ., Wozniak DJ. Psl Produced by Mucoid Pseudomonas aeruginosa Contributes to the Establishment of Biofilms and Immune Evasion. *mBio* 2017; 8: e00864-17


Kang D., Kirienko NV. High-Throughput Genetic Screen Reveals that Early Attachment and Biofilm Formation Are Necessary for Full Pyoverdine Production by Pseudomonas aeruginosa. *Frontiers in Microbiology* 2017; 8: ArNo: 1707

Kenna DTD., Lilley D., Coward A., Martin K., Perry C., Pike R., Hill R., Turton JF. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. *Journal of Medical Microbiology* 2017; 66: 490 - 501

Kishta OA., Guo Y., Mofarrah M., Stana F., Lands LC., Hussain SNA. Pulmonary Pseudomonas aeruginosa infection induces autophagy and proteasome proteolytic pathways in skeletal muscles: effects of a pressurized whey protein-based diet in mice. *Food & Nutrition Research* 2017; 61: ArNo: 1325309

Lee K., Yoon SS. Pseudomonas aeruginosa Biofilm, a Programmed Bacterial Life for Fitness. *Journal of Microbiology and Biotechnology* 2017; 27: 1053 - 1064

Linnane B., Collins L., Bussmann N., O’Connell NH., Dunne CP. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens. *Journal of Hospital Infection* 2017; 96: 397 - 398


Mauders E., Welch M. Matrix exopolysaccharides; the sticky side of biofilm formation. *FEMS Microbiology Letters* 2017; 364: 13:fnx120


Noto MJ., Burns WJ., Beavers WN., Skaar EP.
Mechanisms of Pyocyanin Toxicity and Genetic Determinants of Resistance in Staphylococcus aureus
Journal of Bacteriology 2017; 199: 17:UNS P e00221

O’Brien S., Fothergill JL.
The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung
FEMS Microbiology Letters 2017; 364: 15:fnx128

Oh J., Li XH., Kim SK., Lee JH.
Post-secretionary activation of Protease IV by quorum sensing in Pseudomonas aeruginosa
Scientific Reports 2017; 7: ArNo: 4416

Orazi G., O’Toole GA.
Pseudomonas aeruginosa Alters Staphylococcus aureus Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infec
mBio 2017; 8: 4:e00873-17

Pires DP., Dotsch A., Anderson EM., Hao YA., Khursigara CM., Lam JS., Sillankorva S., Azeredo J.
A Genotypic Analysis of Five P-aeruginosa Strains after Biofilm Infection by Phages Targeting Different Cell Surface Receptors
Frontiers in Microbiology 2017; 8: ArNo: 1229

Poonja A., Heirali A., Workentine M., Storey DG., Somayaji R., Rabin HR., Surette MG., Parkins MD.
Effect of freezing sputum on Pseudomonas aeruginosa population heterogeneity
Journal of Cystic Fibrosis 2017; 16: 353 - 357

Prior AR., Gunaratnam C., Humphreys H.
Ralstonia species - do these bacteria matter in cystic fibrosis?
Paediatric Respiratory Reviews 2017; 23: 78 - 83

Psoter KJ., De Roos AJ., Wakefield J., Mayer JD., Rosenfeld M.
Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis
BMC Infectious Diseases 2017; 17: ArNo: 411

Rautema V., Green HD., Jones AM., Rautema-Richardson R.
High level of beta-(1,3)-D-glucan antigenemia in cystic fibrosis in the absence of invasive fungal disease
Diagnostic Microbiology and Infectious Disease 2017; 88: 316 - 321

Reddy A., Greenberger PA.
Allergic Bronchopulmonary Aspergillosis
Journal of Allergy and Clinical Immunology-in Practice 2017; 5: 866 - 867

Reece E., Segurado R., Jackson A., McClean S., Renwick J., Greally P.
Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis
BMC Pulmonary Medicine 2017; 17: ArNo: 70

Rieger M., Mauch H., Hakenbeck R.
Long Persistence of a Streptococcus pneumoniae 23F Clone in a Cystic Fibrosis Patient
msphere 2017; 2: 3:e00201-17

Roux D., Weatherholt M., Clark B., Gadjeva M., Renaud D., Scott D., Skurnik D., Pribe GP., Pier G., Gerard C., Yoder-Himes DR.
Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa
Infection and Immunity 2017; 85: 6:e00765

Sabino R., Carolino E., Moss RB., Banaei N., Verissimo C., Stevens DA.
Susceptibility of Candida albicans from Cystic Fibrosis Patients
Myкопатология 2017; 182: 863 - 867

Scoffone VC., Chiarelli LR., Trespidi G., Mentasti M., Riccardi G., Buroni S.
Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches
Frontiers in Microbiology 2017; 8: ArNo: 1592

Sherrard LJ., Tay GT., Butler CA., Wood ME., Yerkovich S., Ramsay KA., Reid DW., Moore VL., Kidd TJ., Bell SC.
Tropical Australia is a potential reservoir of non-tuberculous mycobacteria in cystic fibrosis
European Respiratory Journal 2017; 49: 5:1700046

FEMS Microbiology Letters 2017; 364: 14:fnx121

Sobin L., Kawai K., Irace AL., Gergin O., Cunningham M., Sawicki GS., Adil EA.
Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients
Otolaryngology-Head and Neck Surgery 2017; 157: 302 - 308

Stelzer-Brait S., Liu N., Doumit M., D’Cunha R., Belessis Y., Jaffe A., Rawlinson WD.
Association of rhinovirus with exacerbations in young children affected by cystic fibrosis: Preliminary data
Journal of Medical Virology 2017; 89: 1494 - 1497

To KKW., Yip CCC., Yuen KY.
Rhinovirus - From bench to bedside
Journal of the Formosan Medical Association 2017; 116: 996 - 1004

Tognon M., Kohler T., Gdaniec BG., Hao YA., Lam JS., Beaume M., Luscher A., Buckling A., van Delden C.
Co-evolution with Staphylococcus aureus leads to lipopolysaccharide alterations in Pseudomonas aeruginosa
ISME Journal 2017; 11: 2233 - 2243

Williamson KM., Wagner BD., Robertson CE., Johnson EJ., Zemanick ET., Harris JK.
Impact of enzymatic digestion on bacterial community composition in CF airway samples
PEERJ 2017; 5: ArNo: e3362

Yang JY., Toyofuku M., Sakai R., Nomura N.
Influence of the alginate production on cell-to-cell communication in Pseudomonas aeruginosa PA01
Environmental Microbiology Reports 2017; 9: 239 - 249

Zautner AE., Gross U., Emele MF., Hagen RM., Frickmann H.
More Pathogenicity or Just More Pathogens?- On the Interpretation Problem of Multiple Pathogen Detections with Diagnostic Multiplex Assays
Frontiers in Microbiology 2017; 8: ArNo: 1210

Nutrition

Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines
Journal of Cystic Fibrosis 2017; 16: 510 - 518

Filigono SS., Robson SM., Szczesniak RD., Chamberlin LA., Baker MA., Sullivan SM., Kroner J., Powers SW.
Macronutrient intake in preschoolers with cystic fibrosis and the relationship between macronutrients and growth
Journal of Cystic Fibrosis 2017; 16: 519 - 524

Hloch O., Charvat J., Fila L., Jan H.
Immunonutrition in patients with cystic fibrosis leads to drop of serum amyloid A and increase of oxidative stress
Journal of Clinical Biochemistry and Nutrition 2017; 60: 176 - 179
Vitamin K supplementation for cystic fibrosis (Review)
Cochrane Database of Systematic Reviews 2017; : 8:CD000942

Li L., Krause L., Somerset S.
Associations between micronutrient intakes and gut microbiota in a group of adults with cystic fibrosis
Clinical Nutrition 2017; 36: 1097 - 1104

Mandal A., Priyadarshini M., Jat K., Kabra SK.
Infantile Tremor Syndrome and Subdural Hemorrhage in an Infant with Cystic Fibrosis
Journal of Tropical Pediatrics 2017; 63: 328 - 332

Murphy AJ., Hill RJ., Buntain H., White M., Brookes D., Davies PSW.
Nutritional status of children with clinical conditions
Clinical Nutrition 2017; 36: 788 - 792

Okebukola PO., Kansra S., Barrett J.
Vitamin E supplementation in people with cystic fibrosis (Review)
Cochrane Database of Systematic Reviews 2017; : 3:CD0009422

Pincikova T., Paquin-Proulx D., Sandberg JK., Flodstrom-Tullberg M., Hjelte L.
Vitamin D treatment modulates immune activation in cystic fibrosis
Clinical and Experimental Immunology 2017; 189: 359 - 371

Smyth RL., Rayner O.
Oral calorie supplements for cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 5:CD000406

Woestenenk JW., Schulkes DA., Schipper HS., van der Ent CK., Houwen RHJ.
Dietary intake and lipid profile in children and adolescents with cystic fibrosis
Journal of Cystic Fibrosis 2017; 16: 410 - 417

Physiotherapy

Brown SD., White R., Tobin P.
Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment

Gorman J., Sparrow E., Krautbauer K.
Fluid mechanics and sound generation for lung-clearance therapy Advanced design modality for a biomedical therapeutic device

Hortal MCR., Nygren-Bonnier M., Hjelte L.
Non-invasive Ventilation as Airway Clearance Technique in Cystic Fibrosis
Physiotherapy Research International 2017; 22: 3:e1667

Konstan MW., Wagener JS., VanDevanter DR., Pasta DJ., Millar SJ., Morgan WJ.
Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention
Pediatric Pulmonology 2017; 52: 1013 - 1019

Morrison L., Innes S.
Oscillating devices for airway clearance in people with cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 5:CD0006842

Psychosocial

Aguir KCA., Marson FAL., Gomez CCG., Pereira MC., Paschoal IA., Ribeiro AF., Ribeiro JD.
Revista Portuguesa de Pneumologia 2017; 23: 179 - 192

Bosch B., Bilto D., Sonnay P., Rajaith KS., Mak DYG., Ishiguro H., Gulmans V., Thomas M., Cuppens H., Amaral M., De Boeck K.
Ethnicity impacts the cystic fibrosis diagnosis: A note of caution
Journal of Cystic Fibrosis 2017; 16: 488 - 491

Broekema K., Weber KM.
Disclosures of Cystic Fibrosis-Related Information to Romantic Partners
Qualitative Health Research 2017; 27: 1575 - 1585

Christofides E., Stroud K., Tullis DE., O'Doherty K.
The Meanings of Helping: An Analysis of Cystic Fibrosis Patients' Reasons for Participating in Biomedical Research

Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis
Journal of Pediatrics 2017; 184: 165 - +

Mikesell CL., Kempainen RR., Laguna TA., Menk JS., Wey AR., Gaillard PR., Regelmann WE.
Objective Measurement of Adherence to Out-Patient Airway Clearance Therapy by High-Frequency Chest Wall Compression in Cystic Fibrosis
Respiratory Care 2017; 62: 920 - 927

Moola FJ., Henry LAV., Huyen E., Stacey JA., Faulkner GEJ.
They know it's safe - they know what to expect from that face: perceptions towards a cognitive-behavioural counselling programme among caregivers of children with cystic fibrosis
Journal of Clinical Nursing 2017; 26: 2932 - 2943

Morton RW., Elphick HE., Edwards E., Daw WJ., West NS.
Investigating the feasibility of text message reminders to improve adherence to nebulized medication in children and adolescents with cystic fibrosis
Patient Preference and Adherence 2017; 11: 861 - 869

Price DM., Knotts SE.
Communication, Comfort, and Closure for the Patient With Cystic Fibrosis at the End of Life: The Role of the bedside Nurse
Journal of Hospice & Palliative Nursing 2017; 19: 298 - 302

Smyth W., Abernethy G., Jessup M., Douglas T., Shields L.
Family-centred care in cystic fibrosis: a pilot study in North Queensland, Australia
Journal of Cystic Fibrosis 2017; 16: 488 - 489

Tappenden P., Sadler S., Wildman M.
An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis
Pharmacoconomics 2017; 35: 647 - 659

Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up
European Journal of Pediatrics 2017; 176: 1047 - 1054

Ward N., Stiller K., Rowe H., Holland AE.
The psychometric properties of the Leicester Cough Questionnaire and Respiratory Symptoms in CF tool in cystic fibrosis: A preliminary study
Journal of Cystic Fibrosis 2017; 16: 425 - 432

Zobell JT., Schwab E., Collingridge DS., Ball C., Noheave R., Asfour F.
Impact of pharmacy services on cystic fibrosis medication adherence
Pediatric Pulmonology 2017; 52: 1006 - 1012
Pulmonology

Belanger AR., Nguyen K., Osman U., Gilbert CR., Allen K., Al Rais AF., Yarmus L., Akullian JA.

Pleural effusions in non-transplanted cystic fibrosis patients


Myeloperoxidase treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids
Naunyn-schmiedebergs Archives of Pharmacology 2017; 390: 775 - 790

Cook DP., Adam RJ., Zarei K., Deonovich B., Stroik MR., Gansemer ND., Meyerholz DK., Au RF., Stoltz DA.

CF airway smooth muscle transcriptome reveals a role for PYK2
JCI Insight 2017; 2: 17:e95332

FlightWG., Barry PJ., Bright-Thomas RJ., Butterfield S., Ashleigh R., Jones AM.

Outcomes Following Bronchial Artery Embolisation for Haemoptysis in Cystic Fibrosis
Cardiovascular and Interventional Radiology 2017; 40: 1164 - 1168


beta 1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections
Cell Host & Microbe 2017; 21: 707 -

Halderman AA., West N., Benke J., Roxbury CR., Hall DA.

Comparison of Ambient and Atmospheric Pressure Ion Sources for Cystic Fibrosis Exhaled Breath Condensate Ion Mobility-Mass Spectrometry

Radiology

Averill S., Lubner MG., Menias CO., Bhalla S., Mellnick VM., Kennedy TA., Pickhardt PJ.

Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease
American Journal of Roentgenology 2017; 209: 3 - 18

Caudri D., Zitter D., Bronsveld I., Tiddens H.

Is sweat chloride predictive of severity of cystic fibrosis lung disease assessed by chest computed tomography?
Pediatric Pulmonology 2017; 52: 1135 - 1141

Kahn J., Kaul D., Grupp U., Boning G., Renz D., Staab D., Schreiter V., Streitparth F.

Computed Tomography in Cystic Fibrosis: Combining Low-Dose Techniques and Iterative Reconstruction
Journal of Computer Assisted Tomography 2017; 41: 668 - 674

Kolodziej M., de Veer MJ., Cholewa M., Egan GF., Thompson BR.

Lung function imaging methods in Cystic Fibrosis pulmonary disease
Respiratory Research 2017; 18: ArNo: 96

Krueger-Ziolek S., Schullicke B., Gong B., Muller-Lisse U., Moeller K.

EIT based pulsatile impedance monitoring during spontaneous breathing in cystic fibrosis
Physiological Measurement 2017; 38: 1214 - 1225


Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI
Thorax 2017; 72: 760 - 762

Rosenow T., Ramsey K., Turkovic L., Murray CP., Mok LC., Hall GL., Stick SM.

Air trapping in early cystic fibrosis lung disease
Pediatric Pulmonology 2017; 52: 1150 - 1156

Somayaji R., Goss CH., Khan U., Neradilek M., Neuzil KM., Ortiz JR.

Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study
Clinical Infectious Diseases 2017; 64: 1760 - 1767

Sun A., Phelps T., Yao CY., Venkatesh AG., Conrad D., Hall DA.

Smartphone-Based pH Sensor for Home Monitoring of Pulmonary Exacerbations in Cystic Fibrosis
Sensors 2017; 17: 6:1245

Szczesniak R., Heitze SL., Stanojevic S., Haemoptysis in Cystic Fibrosis
Thorax 2017; 72: 760 - 762


Pleural effusions in non-transplanted cystic fibrosis patients


Myeloperoxidase treatment of CF lung infection and inflammation: complex analyses for enigmatic lipids
Naunyn-schmiedebergs Archives of Pharmacology 2017; 390: 775 - 790

Cook DP., Adam RJ., Zarei K., Deonovich B., Stroik MR., Gansemer ND., Meyerholz DK., Au RF., Stoltz DA.

CF airway smooth muscle transcriptome reveals a role for PYK2
JCI Insight 2017; 2: 17:e95332

FlightWG., Barry PJ., Bright-Thomas RJ., Butterfield S., Ashleigh R., Jones AM.

Outcomes Following Bronchial Artery Embolisation for Haemoptysis in Cystic Fibrosis
Cardiovascular and Interventional Radiology 2017; 40: 1164 - 1168


beta 1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections
Cell Host & Microbe 2017; 21: 707 -

Halderman AA., West N., Benke J., Roxbury CR., Lin SY.

FSO8del genotype in endoscopic sinus surgery: do differences in outcomes exist between genotypic subgroups?
International Forum of Allergy & Rhinology 2017; 7: 459 - 466

Moran F., Bradley JM., Piper AJ.

Non-invasive ventilation for cystic fibrosis
Cochrane Database of Systematic Reviews 2017; : 2:CD002769

Occelli A., Soize S., Ranc C., Giovannini-Chami L., Bailly C., Leoloute B., Boyer C., Baque-Juston M.

Bronchocele density in cystic fibrosis as an indicator of allergic bronchopulmonary aspergillosis: A preliminary study

Paul L.

Is bronchoscopy an obsolete tool in cystic fibrosis? The role of bronchoscopy in cystic fibrosis and its clinical use
Journal of Thoracic Disease 2017; 9:

Pittman JE., Noah H., Calloway HE., Davis SD., Leigh MW., Drumm M., Sage SD., Accurso FJ., Knowles MR., Sontag MK.

Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginoasa infection
Pediatrics 2017; 12: 5:e0177215

Sandefur CI., Boucher RC., Elston TC.

Mathematical model reveals role of nucleotide signaling in airway surface liquid homeostasis and its dysregulation in cystic fibrosis
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: E7272 - E7281

Scott LK., Toner R.

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
Lung 2017; 195: 397 - 401
Therapy

Aali M., Caldwell A., House K., Zhou J., Chappe V., Lehmann C.
Iron chelation as novel treatment for lung inflammation in cystic fibrosis
Medical Hypotheses 2017; 104: 86 - 88

Abidin NZ., Haq IJ., Gardner Al., Brodlie M.
Ataluren in cystic fibrosis: development, clinical studies and where are we now?
Expert Opinion on Pharmacotherapy 2017; 18: 1363 - 1371

Ayoub N., Thamboo A., Habib A., Nayak JV., Hwang PH.
Determinants and outcomes of upfront surgery versus medical therapy for chronic rhinosinusitis in cystic fibrosis
International Forum of Allergy & Rhinology 2017; 7: 450 - 458

Baravalle-Einaudi M., Dufeu N., Dupont C., Vecellio L., Delaïs B., Carsin A., Dubus JC.
Vibrating mesh nebulizer maintenance by CF patients: Results from a French survey
Pulmonary Pharmacology & Therapeutics 2017; 44: 57 - 60

Chin M., Aaron SD., Bell SC.
The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis
Presse Medecine 2017; 46: E139 - E164

Corcoran TE., Godovitch JE., Donn KH., Busick DR., Goralski J., Locke LW., Markovetz MR., Myburg MM., Muthukrishnan A., Weber L., Lacy RT., Pilewski JM.
Overnight delivery of hypertonic saline by nasal cannula aerosol for cystic fibrosis
Pediatric Pulmonology 2017; 52: 1142 - 1149

Corti A., Griese M., Hector A., Pompella A.
Increasing sputum levels of gamma-glutamyltransferase may identify cystic fibrosis patients who do not benefit from inhaled glutathione
Journal of Cystic Fibrosis 2017; 16: 342 - 345

Inhaled dry powder manitol in children with cystic fibrosis: A randomised efficacy and safety trial
Journal of Cystic Fibrosis 2017; 16: 380 - 387

Di Lullo AM., Scorza M., Amato F., Cogmena M., Raia V., Maiuri L., Iardi G., Cantone E., Castaldo G., Iengo M.
An "ex vivo model" contributing to the diagnosis and evaluation of new drugs in cystic fibrosis
Acta Otorhinolaryngologica Italica 2017; 37: 207 - 213

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR
Journal of Cystic Fibrosis 2017; 16: 371 - 379

Edgeworth D., Keating D., Ellis M., Button B., Williams E., Clark D., Tierney A., Heritier S., Kotsimbos T., Wilson J.
Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment
Clinical Science 2017; 131: 2057 - 2045

Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment
Clinical Science 2017; 131: 2057 - 2045

Fajic I., Wainwright CE.
New treatments targeting the basic defects in cystic fibrosis
Presse Medecine 2017; 46: E165 - E175

Ferreira ACM., Marson FAL., Cohen MA., Bertuzzo CS., Levy CE., Ribeiro AF., Ribeiro JD.
Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis
Lung 2017; 195: 431 - 439

Guichard MJ., Patil HP., Koussoropis SJ., Wattiez R., Leal T., Vanbever R.
Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy
International Journal of Pharmaceutics 2017; 524: 159 - 167
Immediate effects of lumacaftor/ivacaftor crossover study in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomized, placebo-controlled, phase 3 trial

van Koningsbruggen RJ., Strang A., Fischer AJ., Chidekel A.
Pseudomonas eradication and clinical effectiveness of ivacaftor in four Hispanic patients with S549N

Molinski SV., Ahmadi S., Ip W., Ouyang H., Villella A., Miller JP., Lee PS., Kullerupera K., Du K., Di Paola M., Eckford PDW., Laselva O., Huan LJ., Wellhauer L., Li E., Ray PN., Pomes R., Moraes TJ., Gonska T., Ratjen F., Bear Okrambi (R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue

Molinski SV., Ahmed S., Ip W., Ouyang H., Villella A., Miller JP., Lee PS., Kullerupera K., Du K., Di Paola M., Eckford PDW., Laselva O., Huan LJ., Wellhauer L., Li E., Ray PN., Pomes R., Moraes TJ., Gonska T., Ratjen F., Bear Okrambi (R) and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue

EMBO Molecular Medicine 2017; 9: 1224 - 1243

Nenna R., Midulla F., Carnio J., De Castro G., Zicari AM., Indinnimeo L., Cimino G., Trolani P., Quattrucci S., Tancredi G.
Effects of inhaled hypertonic (7%) saline on lung function test in preschool children with cystic fibrosis: results of a crossover, randomized clinical trial

Italian Journal of Pediatrics 2017; 43: ArNo: 60

O'Neill K., Moran F., Tunney MM., Elborn JS., Bradbury J., Downey DG., Rendall J., Bradley JM.
Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomized crossover study

BMJ Open Respiratory Research 2017; 4: 1:UNSP e000168

Popowicz N., Wood J., Tai A., Morey S., Mulrennan S.
Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease

Journal of Cystic Fibrosis 2017; 16: 392 - 394

Transplantation

Burcham P., Sarzynski L., Khalfoun S., Novak KJ., Miller JC., Tumin D., Hayes D.
Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis

Pediatric Drugs 2017; 19: 339 - 346

Ramos KJ., Somayaji R., Lease ED., Goss CH., Aitken ML.
Cystic fibrosis physicians’ perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States

BMC Pulmonary Medicine 2017; 17: ArNo: 21

Stephenson AL., Eykes J., Berthiaume Y., Singer LG., Chaparro C., Aaron SD., Whitmore GA., Stanojevic S.
A clinical tool to calculate post-transplant survival using pre-transplant clinical characteristics in adults with cystic fibrosis Clinical Transplantation 2017; 31: 6:e12950

Wan XX., Liu WF., Zheng T., Park JM., Smith DE., Feng MR.
Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis

Xenobiotica 2017; 47: 697 - 704